Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sperogenix Therapeutics
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
AGAMREE® (vamorolone) for DMD received China NMPA approval in December 2024, with exclusive rights for Greater China; leriglitazone (for X-ALD) is in clinical development with Sperogenix holding China rights
- Therapeutic areas
- Metabolic DisordersRare DiseasesHematologyCardiovascularNeurology
- Modalities
- Small moleculeSteroidPPAR-γ agonist
- Industry
- Biotech
02
Partnerships
Santhera Pharmaceuticals (licensing and commercialization of AGAMREE® in Greater China and Southeast Asia)Minoryx Therapeutics (exclusive license for leriglitazone in China)
Beyond the preview
Go deeper on Sperogenix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sperogenix Therapeutics.